Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access
Abstract Classical Hodgkin lymphoma (cHL) is a highly-curable, aggressive form of lymphoma with disparities between international guidelines and treatment in resource-limited countries. We aimed to report outcomes in a multi-centered retrospective cohort of all cHL patients ≥ 18 years old exclusivel...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-07187-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399679272353792 |
|---|---|
| author | Suprang Suttantapidok Smith Kungwankiattichai Weerapat Owattanapanich |
| author_facet | Suprang Suttantapidok Smith Kungwankiattichai Weerapat Owattanapanich |
| author_sort | Suprang Suttantapidok |
| collection | DOAJ |
| description | Abstract Classical Hodgkin lymphoma (cHL) is a highly-curable, aggressive form of lymphoma with disparities between international guidelines and treatment in resource-limited countries. We aimed to report outcomes in a multi-centered retrospective cohort of all cHL patients ≥ 18 years old exclusively treated with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) without positron emission tomograph (PET)-adapted treatment between 2013 and 2022 in Thailand. First-line core treatment goals (FL-CTGs) for a resource-limited middle-income country were also investigated. One hundred ninety-two patients were included (median age 28.0 years, range 15, 79). The patients had an objective response rate of 90%. The 3-year overall survival (OS) was 94.6% (95%CI 89.8%, 97.2%), and the 3-year progression-free survival (PFS) was 62.2% (95%CI 54.2%, 69.3%). Both 3-year OS and PFS rates were higher in patients achieving FL-CTGs compared with those not achieving them in the early stage (Ann Arbor stages I and II) and advanced stage (Ann Arbor stages III and IV) groups. Advanced-stage patients not achieving FL-CTGs had a significantly higher risk of progression, relapse, or all-cause mortality (aHR 3.77, 95%CI 1.74, 8.17; p < 0.001). In conclusion, cHL patients treated exclusively with ABVD without PET-adapted treatment had good survival outcomes and achieving FL-CTGs is essential for good survival outcomes. |
| format | Article |
| id | doaj-art-3d97767a0c8a4e418fa87edb204db458 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-3d97767a0c8a4e418fa87edb204db4582025-08-20T03:38:16ZengNature PortfolioScientific Reports2045-23222025-07-0115111310.1038/s41598-025-07187-zTreatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine accessSuprang Suttantapidok0Smith Kungwankiattichai1Weerapat Owattanapanich2Division of Medicine, Vachira Phuket HospitalDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityAbstract Classical Hodgkin lymphoma (cHL) is a highly-curable, aggressive form of lymphoma with disparities between international guidelines and treatment in resource-limited countries. We aimed to report outcomes in a multi-centered retrospective cohort of all cHL patients ≥ 18 years old exclusively treated with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) without positron emission tomograph (PET)-adapted treatment between 2013 and 2022 in Thailand. First-line core treatment goals (FL-CTGs) for a resource-limited middle-income country were also investigated. One hundred ninety-two patients were included (median age 28.0 years, range 15, 79). The patients had an objective response rate of 90%. The 3-year overall survival (OS) was 94.6% (95%CI 89.8%, 97.2%), and the 3-year progression-free survival (PFS) was 62.2% (95%CI 54.2%, 69.3%). Both 3-year OS and PFS rates were higher in patients achieving FL-CTGs compared with those not achieving them in the early stage (Ann Arbor stages I and II) and advanced stage (Ann Arbor stages III and IV) groups. Advanced-stage patients not achieving FL-CTGs had a significantly higher risk of progression, relapse, or all-cause mortality (aHR 3.77, 95%CI 1.74, 8.17; p < 0.001). In conclusion, cHL patients treated exclusively with ABVD without PET-adapted treatment had good survival outcomes and achieving FL-CTGs is essential for good survival outcomes.https://doi.org/10.1038/s41598-025-07187-zHodgkin lymphomaLimited resourceMiddle-income countriesProcarbazine, PET |
| spellingShingle | Suprang Suttantapidok Smith Kungwankiattichai Weerapat Owattanapanich Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access Scientific Reports Hodgkin lymphoma Limited resource Middle-income countries Procarbazine, PET |
| title | Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access |
| title_full | Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access |
| title_fullStr | Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access |
| title_full_unstemmed | Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access |
| title_short | Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access |
| title_sort | treatment outcomes of abvd in classical hodgkin lymphoma patients from thailand without procarbazine access |
| topic | Hodgkin lymphoma Limited resource Middle-income countries Procarbazine, PET |
| url | https://doi.org/10.1038/s41598-025-07187-z |
| work_keys_str_mv | AT suprangsuttantapidok treatmentoutcomesofabvdinclassicalhodgkinlymphomapatientsfromthailandwithoutprocarbazineaccess AT smithkungwankiattichai treatmentoutcomesofabvdinclassicalhodgkinlymphomapatientsfromthailandwithoutprocarbazineaccess AT weerapatowattanapanich treatmentoutcomesofabvdinclassicalhodgkinlymphomapatientsfromthailandwithoutprocarbazineaccess |